Experimental combo aims to tame dangerous transplant side effect
NCT ID NCT04886726
Summary
This early-stage study is testing whether adding two pregnancy-related hormones (uhCG/EGF) to a standard drug (cyclophosphamide) can safely prevent graft-versus-host disease (GVHD) after a stem cell transplant from a mismatched donor. The trial will enroll 18 adults with blood cancers who need a transplant but lack a perfectly matched donor. Researchers will first check if the combination is safe and find the right dose, while also tracking how many patients develop GVHD and how long they survive.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT -VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henry Ford Hospital
RECRUITINGDetroit, Michigan, 48202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.